Leerink Partners raises Nanobiotix stock price target to $24 on pipeline progress

Leerink Partners raised its price target for Nanobiotix (NASDAQ:NBTX) to $24.00 from $14.00, maintaining an Outperform rating, driven by positive Phase 1 clinical data for its lead radioenhancer NBTXR3 (JNJ-1900) in head-and-neck squamous cell carcinoma. The firm highlighted recent intellectual property reinforcement and promising results presented at ASTRO 2025, suggesting significant commercial opportunities for NBTXR3 despite clinical risks. This analyst upgrade follows the company's robust 558% year-to-date stock performance, reflecting growing investor confidence.

Analysis

Leerink Partners has materially increased its price target for Nanobiotix S.A. (NASDAQ:NBTX) to $24.00 from $14.00, maintaining an Outperform rating. This revision is underpinned by accumulating positive clinical data for its lead asset, the radioenhancer NBTXR3 (JNJ-1900). Specifically, the company presented updated positive results from cohorts 1 and 2 of its Phase I Study 1100 at the ASTRO 2025 annual meeting, evaluating NBTXR3 in combination with checkpoint inhibitors for head-and-neck squamous cell carcinoma. This follows an initial data presentation from cohort 3 at the ImmunoRad conference and is further supported by intellectual property reinforcement through a new patent filing. The collaboration with Johnson & Johnson is viewed as a significant supportive factor that de-risks development. Despite acknowledging inherent clinical and commercial risks, the analyst sentiment is strongly positive, reflecting the drug's potential in large commercial markets. This news builds on the stock's existing momentum, which has seen a 558% year-to-date return, and sets the stage for a near-term catalyst with an upcoming data update on esophageal cancer at ASTRO 2025.

Key Decisions for Investors

• Investors should view the combination of positive Phase 1 data, a significant analyst price target upgrade, and the strategic partnership with Johnson & Johnson as strong validation of NBTXR3's therapeutic potential.
• The upcoming data release from the MD Anderson collaboration evaluating NBTXR3 in esophageal cancer, scheduled for this Wednesday, is a critical near-term catalyst that warrants close attention.
• While the outlook is positive, investors must remain aware of the stock's substantial 558% year-to-date appreciation, which introduces potential for volatility, alongside the inherent clinical and commercial risks associated with a novel biotechnology asset.